Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk : Is Imaging Helpful?
Copyright © 2023 Elsevier Inc. All rights reserved..
Nonalcoholic Fatty Liver Disease (NAFLD) is proving to be a globally prevalent condition. Moreover, NAFLD may be an independent risk factor associated with higher cardiovascular (CVD) morbidity and mortality. Further studies are needed to assess whether NAFLD needs to be included in the atherosclerotic risk score algorithms or whether patients with NAFLD need to be screened early on to assess their CVD risk especially since imaging such as positron emission tomography can be used to assess both NAFLD and CV disease at the same time. Therefore employing cardiovascular imaging modalities to investigate the incidence, extent, and nature of atherosclerotic lesions in NAFLD may be beneficial. Additionally, whether treating NAFLD halts the progression of CVD on imaging remains to be seen. Further research to delineate NAFLD and CVD associations, deciphering screening imaging modalities, and investigating targeted interventions could improve CVD morbidity and mortality in NAFLD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Current problems in cardiology - 49(2023), 1 Pt B vom: 04. Jan., Seite 102065 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Doumas, Stavros A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cpcardiol.2023.102065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361499353 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361499353 | ||
| 003 | DE-627 | ||
| 005 | 20231227132945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cpcardiol.2023.102065 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1230.xml |
| 035 | |a (DE-627)NLM361499353 | ||
| 035 | |a (NLM)37652112 | ||
| 035 | |a (PII)S0146-2806(23)00482-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Doumas, Stavros A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk |b Is Imaging Helpful? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Nonalcoholic Fatty Liver Disease (NAFLD) is proving to be a globally prevalent condition. Moreover, NAFLD may be an independent risk factor associated with higher cardiovascular (CVD) morbidity and mortality. Further studies are needed to assess whether NAFLD needs to be included in the atherosclerotic risk score algorithms or whether patients with NAFLD need to be screened early on to assess their CVD risk especially since imaging such as positron emission tomography can be used to assess both NAFLD and CV disease at the same time. Therefore employing cardiovascular imaging modalities to investigate the incidence, extent, and nature of atherosclerotic lesions in NAFLD may be beneficial. Additionally, whether treating NAFLD halts the progression of CVD on imaging remains to be seen. Further research to delineate NAFLD and CVD associations, deciphering screening imaging modalities, and investigating targeted interventions could improve CVD morbidity and mortality in NAFLD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Tripathi, Shalini |e verfasserin |4 aut | |
| 700 | 1 | |a Kashikar, Aditi |e verfasserin |4 aut | |
| 700 | 1 | |a Khuttan, Akhilesh |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Ashwin |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Harjit |e verfasserin |4 aut | |
| 700 | 1 | |a Canakis, Justin P |e verfasserin |4 aut | |
| 700 | 1 | |a Ashish, Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Dey, Debashish |e verfasserin |4 aut | |
| 700 | 1 | |a Oppenheim, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Dey, Amit Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current problems in cardiology |d 1993 |g 49(2023), 1 Pt B vom: 04. Jan., Seite 102065 |w (DE-627)NLM000219622 |x 1535-6280 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:1 Pt B |g day:04 |g month:01 |g pages:102065 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cpcardiol.2023.102065 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 1 Pt B |b 04 |c 01 |h 102065 | ||